WO2025162493 - ANTI-NECTIN-4 ANTIBODY/LIGAND-DRUG CONJUGATE AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/162493
Publication Date
07.08.2025
International Application No.
PCT/CN2025/075858
International Filing Date
05.02.2025
Title **
[English]
ANTI-NECTIN-4 ANTIBODY/LIGAND-DRUG CONJUGATE AND USE THEREOF
[French]
CONJUGUÉ ANTICORPS ANTI-NECTINE-4/LIGAND-MÉDICAMENT ET SON UTILISATION
[Chinese]
抗Nectin-4抗体、配体药物偶联物及其应用
Applicants **
GAN & LEE PHARMACEUTICALS CO., LTD.
Inventors
JIAO, Jiao
SUN, Yingjie
CHE, Liming
CUI, Menghan
WANG, Jiaxing
LU, Tengfei
Priority Data
202410116532.5
29.01.2024
CN
202410564053.X
08.05.2024
CN
202411388187.7
08.10.2024
CN
202411429922.4
14.10.2024
CN
202411783791.X
06.12.2024
CN
202411429096.3
14.10.2024
CN
202411795873.6
09.12.2024
CN
202411947010.6
27.12.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3731 | |
| EPO | Filing, Examination, Granting | 26471 | |
| Japan | Filing, Examination, Granting | 2803 | |
| South Korea | Filing, Examination, Granting | 3762 | |
| USA | Filing, Examination, Granting | 10640 |
Total:
47,407
Contact Us
Abstract[English]
Provided are an anti-Nectin-4 antibody/ligand-drug conjugate and a use thereof. The anti-Nectin-4 antibody/ligand-drug conjugate can be used for preventing and/or treating Nectin-4-mediated diseases or conditions.[French]
L'invention concerne un conjugué anticorps anti-nectine-4/ligand-médicament et son utilisation. Le conjugué anticorps anti-nectine-4/ligand-médicament peut être utilisé pour prévenir et/ou traiter des maladies ou des affections médiées par la nectine-4.[Chinese]
提供了抗Nectin-4抗体、配体-药物偶联物及其应用。抗Nectin-4抗体、配体-药物偶联物可用于Nectin-4介导的疾病或病症的预防和/或治疗。